| Identification | Back Directory | [Name]
Cefpimizole | [CAS]
84880-03-5 | [Synonyms]
U 63196
Cefpimizol
CEFPIMIZOLE
1-[[(6R)-2-Carboxylato-7α-[[(R)-[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)pyridinium
Pyridinium, 1-[[(6R,7R)-2-carboxy-7-[[(2R)-[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, inner salt
(6R,7R)-7-[[(2R)-2-[(5-carboxy-1H-imidazole-4-carbonyl)amino]-2-phenylacetyl]amino]-8-oxo-3-[[4-(2-sulfonatoethyl)pyridin-1-ium-1-yl]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Pyridinium, 1-[[2-carboxy-7-[[[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, inner salt, [6R-[6α,7β(R*)]]-
cefpimizole:(6r,7r)-7-(((2r)-2-((5-carboxy-1h-IMIDAZOLE-4-carbonyl)amino)-2-phenylacetyl)amino)-8-oxo-3-((4-(2-sulfonatoethyl)pyridin-1-ium-1-yl)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxyli | [Molecular Formula]
C28H26N6O10S2 | [MDL Number]
MFCD00865010 | [MOL File]
84880-03-5.mol | [Molecular Weight]
670.67 |
| Hazard Information | Back Directory | [Description]
Cefpimizole sodium is a third-generation cephalosporin with a spectrum of activity
somewhat narrower than cefotaxime and cefoperazone. | [Originator]
Ajinomoto (Japan) | [Uses]
Antibacterial. | [Definition]
ChEBI: Cefpimizole is a peptide. | [Brand name]
Ajicef; Renilan | [Antimicrobial activity]
A semisynthetic parenteral cephalosporin. It exhibits modest
activity compared to other antipseudomonal cephalosporins.
Like cefoperazone, it is susceptible to many enterobacterial
β-lactamases. In volunteers receiving 0.1–1 g intramuscularly,
mean peak plasma concentrations reached 15–20 and
35–40 mg/L, respectively. There was no accumulation when
the dose was repeated every 8 h for 7 days. No metabolites
have been detected. The plasma elimination half-life is 1.8–
2.1 h. The principal route of elimination is renal, 70–80%
being recovered unchanged in the urine.
Significant pain at the site of infection has been a prominent
adverse event. It is no longer widely available. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Alfa Chemistry
|
| Tel: |
+1 (201) 478-8534 |
| Website: |
www.alfa-chemistry.com |
| Company Name: |
AmplaChem, Inc.
|
| Tel: |
+1 (412) 455-5567 |
| Website: |
www.amplacheminc.com |
| Company Name: |
Amfinecom Inc.
|
| Tel: |
+1 (804) 861-0001 |
| Website: |
www.amfinecom.com |
| Company Name: |
Wonda Science
|
| Tel: |
+1 (514) 581-6866 |
| Website: |
www.wondascience.com |
| Company Name: |
Inter-Chemical Ltd
|
| Tel: |
86-0755-82226643 82192202 |
| Website: |
www.inter-chemical.com |
|